Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

Summary

Although immune checkpoint inhibitors (ICIs) provide a durable response in multiple tumor types, relapse occurs in most patients with solid tumor. However, the benefits of retreatment with ICIs remains controversial. In some studies, retreatment with ICIs has exhibited encouraging efficacy in patients with solid tumors, particularly in melanoma, and non-small cell lung cancer (NSCLC). In this single arm phase 2 trial, we aimed to evaluate the efficacy and safety of the combination of anti-PD1 antibody (zimberelimab) and lenvatinib in patients with advanced cervical cancer who progressed on or after prior ICIs.

Timeline

Start

2023-05-10

Primary completion

2024-07-20

Completion

2026-06-30

Drugs

Indications